MedTrace Logo

A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

NCT06694935 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-01-13

No results posted yet for this study

Summary

This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Non-Alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

QX1206

QX1206 will be administered orally before bedtime

Sponsors & Collaborators

  • 1Globe Health Institute

    lead INDUSTRY

Principal Investigators

  • Andrew Keates, PhD · 1Globe Health Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-06
Primary Completion
2025-07-31
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06694935 on ClinicalTrials.gov